- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03202563
Trial to Evaluate the Efficacy on Glycemic Variability and Safety of Gemigliptin Compared With Dapagliflozin Added on Metformin Alone or Diabetes Medication Naïve Patient in Type 2 Diabetes Mellitus (Stable II Study)
A Multicenter, Randomized, Active-controlled, Parallel Group, Open-label, Phase 4 Trial to Evaluate the Efficacy on Glycemic Variability and Safety of Gemigliptin 50mg q.d., Versus Dapagliflozin 10mg q.d. Added to Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone or Diabetes Medication Naïve Patient
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of, 06351
- Samsung Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with type 2 diabetes mellitus of 20~70years of age at the time of Visit 1 (Screening)
Patients with HbA1c measured in the local lab ranged from 7 to 11%satisfying the following conditions at the time of Visit 1(Screening)
- Type 2 diabetes mellitus medication naïve patients or patients who had not taken diabetes medication other than metformin within 8 weeks prior to Visit 1(Screening)
- For patients who have been taking metformin alone within 12 weeks prior to visit 1(Screening) and had taken at least 1000 mg of metformin daily without dose adjustment for 4 weeks prior to Visit 1(Screening)
- Patients who have signed an informed consent themselves after receiving explanation about the objectives, methods, effects, etc. of the clinical study
Patients who are applicable to one of the three in the following. 1) Surgically infertile patients 2) Postmenopausal female patients of ≥45 years of age for whom ≥2 years elapsed since their last menstruation 3) Premenopausal fertile female patients or surgically non-infertile male patients who have agreed to use at least 2 kinds of contraceptive measures (certainly including one of the barrier methods) to avoid pregnancy until 14 days after the last dose of the investigational product
- Barrier methods: Condom, Diaphragm, Cervical cap(Pessary), Spermicide
- Hormonal methods: Pills, Injection(Depot), Skin patch, Hormonal implant(Implanon), Vaginal ring
- Intrauterine Devices(IUDs): Cooper IUD(Loop), Hormonal IUD(Mirena)
- Natural methods: Basic body temperature, Ovulation period, Coitus interruptus, Abstinence
Exclusion Criteria:
- Patients with type 1 diabetes mellitus*, Diabetic ketoacidosis, Diabetic coma, Diabetic pre-coma
- Patients with Gestational diabetes, or secondary diabetes
- Patients with Body Mass Index(BMI) >40 kg/m2 at the time of Visit 1(Screening)
Patients with a history of the following
- Patients with NYHA Class III, IV congestive heart failure or arrhythmia requiring treatment at the time of Visit 1(Screening)
- Patients whose TSH level is out of the normal range and who have thyroidal dysfunction requiring drug therapy at the time of Visit 1(Screening) (However, those who have been taking thyroid hormone at a fixed dose since previous 6 weeks prior to Visit 1[Screening] and whose TSH level is within the normal range can participate in the study.)
- Patients with a glomerular filtration rate (eGFR) less than 60 mL/min /1.73 m2, dnd stage renal disease, dialysis or with renal disease that may result from conditions such as cardiovascular shock, acute myocardial infarction and sepsis, or patients with renal insufficiency at the time of Visit 1(Screening)
- Patients who are receiving intravenous iodine contrast agents at the time of visit 1(Screening) or planned during the clinical trial period (eg, intravenous urography, venous cholangiography, angiography, computed tomography using contrast media, etc.) ). For patients who have received this test, they can re-evaluate the renal function 48 hours after the test and only participate in clinical trials after they have been found to be normal.
- Patients with pulmonary embolism, severe pulmonary dysfunction, or who are susceptible to be accompanied by hypoxemia at the time of Visit 1(Screening)
- Patients on drug therapy due to gastrointestinal disturbance including dehydration, diarrhea, and vomiting at the time of Visit 1(Screening) Patients with severe infection or severe trauma at the time of Visit 1(Screening)
- Patients with malnutrition status, starvation status, weakness status, pituitary insufficiency or adrenal insufficiency at the time of Visit 1(Screening)
- Patients with a history of diabetic ketoacidosis or hyperosmolar non-ketotic coma within 12 weeks prior to Visit 1(Screening)
- Patients with a history of myocardial infarction, unstable angina, and coronary artery bypass graft(CABG) within 12 weeks prior to Visit 1(Screening)
- Patients who had had a surgical operation within 4 weeks prior to Visit 1(Screening) (excluding minor surgeries without restriction on food and fluid intake) or who are scheduled to have a significant surgery during the study period
- Patients with a history of alcoholism or drug addiction within 12weaks prior to Visit 1(Screening)
- Patients with a history of malignant tumors within 5 years prior to Visit 1(Screening). However, patients with basal cell or squamous cell skin cancer, or in situ cervical cancer treated properly can participate in the study.
Patients with the outcomes of the laboratory tests performed at Visit 1(Screening) applicable to the criteria below
- Bilirubin >2 × upper limit of normal(ULN)
- AST/ALT >3 × ULN
Patients with a history of hypersensitivity reactions to the drugs below
- Gemigliptin or drugs belonging to dipeptidyl-peptidase4(DPP4) inhibitors
- Dapagliflozin or drugs belonging to Sodium/glucose co transport-2(SGLT-2) inhibitor
- Metformin or drugs belonging to biguanides
Patients who were administered the drugs below
- Patients who had been administered anti-obesity drugs within 4 weeks prior to Visit 1(Screening)
- Patients who had been administered insulin or GLP-1 analogues within 8 weeks prior to Visit 1(Screening)
- Patients who had been administered warfarin, dicoumarin, and digoxin within 4 weeks prior to Visit 1(Screening)
- Patients who are being administered any of the strong CYP3A4 inducers (rifampicin[rifampin], dexamethasone, phenytoin, carbamazepine, rifabutin, phenobarbital) at the time of Visit 1(Screening)
- Patients who had been being administered glucocorticoids continuously within 2 weeks prior to Visit 1(Screening) or who are required to take glucocorticoids continuously in the future
- Patients with a genetic problems such as Galactose intolerance, Lapp lactose deficiency, Glucose-galactose malabsorption)
- Female patients who are pregnant or lactating
- Patients who have an experience of participation in another clinical study within 12 weeks prior to Visit1(screening)
- Patients who are otherwise considered to be ineligible for this study on investigators' judgment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Gemigliptin 50mg
the subjects should visit a study site 4 times during the treatment period for about 12 weeks in total. Drug: Gemigliptin Drug: Metformin Procedure: Diet/exercise questionnaire Procedure: Continuous Glucose Monitoring System(CGMS) |
For patients who have been randomized to Gemigliptin(Experimental arm), the patients continue to take a gemigliptin 50mg 1 tablet by once daily during study treatment period(Visit 3(day 1)~Visit 6(day 91))
doing exercise with about intermediate intensity(50~70%) for ≥150minutes in total over at least 3 times(every other day) weekly should be recommended and regular diet without greater changes in life style as much as possible during the whole study period. the questionnaire regarding diet/exercise will be collected at -day 6, day 1, day29, day85, day 91
For patients who have been screening completely, the subjects will be attached CGMS(ipro-2) twice from Visit 2(-day 6) to Visit 3(day 1) and Visit 5(day 85) to Visit 6(day 91)
For patients who have been taking metformin, the patients who had taken at least 1000 mg of metformin daily and continue the same dosage and administration as before participant in the study
|
Active Comparator: Dapagliflozin 10mg
the subjects should visit a study site 4 times during the treatment period for about 12 weeks in total. Drug: Dapagliflozin Drug: Metformin Procedure: Diet/exercise questionnaire Procedure: Continuous Glucose Monitoring System(CGMS) |
doing exercise with about intermediate intensity(50~70%) for ≥150minutes in total over at least 3 times(every other day) weekly should be recommended and regular diet without greater changes in life style as much as possible during the whole study period. the questionnaire regarding diet/exercise will be collected at -day 6, day 1, day29, day85, day 91
For patients who have been screening completely, the subjects will be attached CGMS(ipro-2) twice from Visit 2(-day 6) to Visit 3(day 1) and Visit 5(day 85) to Visit 6(day 91)
For patients who have been taking metformin, the patients who had taken at least 1000 mg of metformin daily and continue the same dosage and administration as before participant in the study
For patients who have been randomized to Dapagliflozin(Active Comparator arm), the patients continue to take a dapagliflozin 10mg 1 tablet by once daily during study treatment period(Visit 3(day 1)~Visit 6(day 91))
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes from baseline MAGE(Mean amplitude of glycemic excursion) at week 12
Time Frame: baseline (visit 2~visit3) and week 12 (visit 5~visit 6)
|
MAGE will be calculated from MBG which has been measured by CGMS(Continuous Glucose Monitoring System) during CGM period(visit 2~visit 3, visit 5~visit 6)
|
baseline (visit 2~visit3) and week 12 (visit 5~visit 6)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes from baseline MBG(Mean Blood Glucose) at week 12
Time Frame: baseline (visit 2~visit3) and week 12 (visit 5~visit 6)
|
MBG is a mean blood glucose measured by CGMS(Continuous Glucose Monitoring System) during CGM period(visit 2~visit 3, visit 5~visit 6)
|
baseline (visit 2~visit3) and week 12 (visit 5~visit 6)
|
Changes from baseline SD(Standard Deviation) at week 12
Time Frame: baseline (visit 2~visit3) and week 12 (visit 5~visit 6)
|
SD is a standard deviation of MBG measured by CGMS(Continuous Glucose Monitoring System) during CGM period(visit 2~visit 3, visit 5~visit 6)
|
baseline (visit 2~visit3) and week 12 (visit 5~visit 6)
|
Changes from baseline CV(Coefficient of variance) at week 12
Time Frame: baseline (visit 2~visit3) and week 12 (visit 5~visit 6)
|
CV is a coefficient of variance which is MBG divided by SD measured by MBG during CGM period(visit 2~visit 3, visit 5~visit 6)
|
baseline (visit 2~visit3) and week 12 (visit 5~visit 6)
|
Changes from baseline hsCRP at week 12
Time Frame: baseline (visit 2) and week 12 (visit 5)
|
baseline (visit 2) and week 12 (visit 5)
|
|
Changes from baseline Nitrotyrosine at week 12
Time Frame: baseline (visit 2) and week 12 (visit 5)
|
baseline (visit 2) and week 12 (visit 5)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes of HbA1c at each visit
Time Frame: baseline(visit 2), week 5(visit 4), week 13(visit 5)
|
values of parameters at the corresponding visit - values of parameters at visit 2(baseline)
|
baseline(visit 2), week 5(visit 4), week 13(visit 5)
|
Changes of Fasting plasma glucose at each visit
Time Frame: baseline(visit 2), week 5(visit 4), week 13(visit 5)
|
values of parameters at the corresponding visit - values of parameters at visit 2(baseline)
|
baseline(visit 2), week 5(visit 4), week 13(visit 5)
|
Changes of Fasting serum insulin at each visit
Time Frame: baseline(visit 2), week 5(visit 4), week 13(visit 5)
|
values of parameters at the corresponding visit - values of parameters at visit 2(baseline)
|
baseline(visit 2), week 5(visit 4), week 13(visit 5)
|
Changes of Glycated albumine at each visit
Time Frame: baseline(visit 2), week 5(visit 4), week 13(visit 5)
|
values of parameters at the corresponding visit - values of parameters at visit 2(baseline)
|
baseline(visit 2), week 5(visit 4), week 13(visit 5)
|
Changes of baseline HOMA-β at week 13
Time Frame: baseline(visit 2), week 13(visit 5)
|
baseline(visit 2), week 13(visit 5)
|
|
Changes of baseline HOMA-IR at week 13
Time Frame: baseline(visit 2), week 13(visit 5)
|
baseline(visit 2), week 13(visit 5)
|
|
Changes of baseline LDL-C at week 13
Time Frame: baseline(visit 2), week 13(visit 5)
|
baseline(visit 2), week 13(visit 5)
|
|
Changes of baseline HDL-C at week 13
Time Frame: baseline(visit 2), week 13(visit 5)
|
baseline(visit 2), week 13(visit 5)
|
|
Changes of baseline Total Cholesterol at week 13
Time Frame: baseline(visit 2), week 13(visit 5)
|
baseline(visit 2), week 13(visit 5)
|
|
Changes of baselineTriglyceride at week 13
Time Frame: baseline(visit 2), week 13(visit 5)
|
baseline(visit 2), week 13(visit 5)
|
|
Changes of baseline BMI at week 13
Time Frame: baseline(visit 2), week 13(visit 5)
|
baseline(visit 2), week 13(visit 5)
|
|
Changes of baseline Body weight at week 13
Time Frame: baseline(visit 2), week 13(visit 5)
|
baseline(visit 2), week 13(visit 5)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jaehyen Kim, Samsung Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LG-DPCL017
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
-
Newsoara Biopharma Co., Ltd.RecruitingT2DM (Type 2 Diabetes Mellitus)China
-
Shanghai Golden Leaf MedTec Co. LtdActive, not recruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on Gemigliptin 50mg
-
LG ChemCompleted
-
LG ChemCompletedDiabetes Mellitus, Type 2Korea, Republic of
-
LG Life SciencesCompletedType 2 Diabetes MellitusKorea, Republic of
-
Seoul National University Bundang HospitalLG Life SciencesUnknownCancer | Cisplatin Adverse ReactionKorea, Republic of
-
LG ChemCompletedHealthy Male VolunteersKorea, Republic of
-
LG Life SciencesCompletedType 2 Diabetes MellitusKorea, Republic of
-
LG Life SciencesCompleted
-
Bangkok Metropolitan Administration Medical College...CompletedDiabetic NephropathiesThailand